Literature DB >> 16507770

Innate immunity defects in Hermansky-Pudlak type 2 syndrome.

Stefania Fontana1, Silvia Parolini, William Vermi, Sarah Booth, Federico Gallo, Marta Donini, Marzia Benassi, Francesca Gentili, Daniela Ferrari, Lucia D Notarangelo, Patrizia Cavadini, Emanuela Marcenaro, Stefano Dusi, Marco Cassatella, Fabio Facchetti, Gillian M Griffiths, Alessandro Moretta, Luigi D Notarangelo, Raffaele Badolato.   

Abstract

Adaptor protein-3 (AP-3) is an ubiquitous cytoplasmic complex that shuttles cargo proteins from the trans-Golgi and a tubular-endosomal compartment to endosome-lysosome-related organelles. Lack of the beta3A subunit of this complex causes Hermansky-Pudlak syndrome type 2, an autosomal recessive disease characterized by partial albinism, prolonged bleeding tendency, and immunodeficiency. To investigate the pathogenesis of immunodeficiency, we studied natural killer (NK) cells and neutrophil functions in 2 previously unreported siblings affected by Hermansky-Pudlak type 2 syndrome. In both patients we observed a dramatic reduction of cytolytic activity of freshly isolated and of IL-2-activated NK cells. Levels of perforin were reduced in unstimulated NK cells, thereby accounting for the impairment of NK cytolitic activity. In addition, analysis of neutrophils in these patients demonstrated that intracellular elastase content was largely reduced while CD63 expression on plasma membrane was substantially increased. Taken together, these observations suggest that type 2 Hermansky-Pudlak syndrome is characterized by defects of innate immunity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16507770     DOI: 10.1182/blood-2005-11-4398

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

Review 1.  Mechanisms of protein delivery to melanosomes in pigment cells.

Authors:  Anand Sitaram; Michael S Marks
Journal:  Physiology (Bethesda)       Date:  2012-04

Review 2.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Interstitial lung disease and pulmonary fibrosis in Hermansky-Pudlak syndrome type 2, an adaptor protein-3 complex disease.

Authors:  Bernadette R Gochuico; Marjan Huizing; Gretchen A Golas; Charles D Scher; Maria Tsokos; Stacey D Denver; Melissa J Frei-Jones; William A Gahl
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 4.  Disorders of lysosome-related organelle biogenesis: clinical and molecular genetics.

Authors:  Marjan Huizing; Amanda Helip-Wooley; Wendy Westbroek; Meral Gunay-Aygun; William A Gahl
Journal:  Annu Rev Genomics Hum Genet       Date:  2008       Impact factor: 8.929

Review 5.  Natural killer cell cytotoxicity: how do they pull the trigger?

Authors:  Nicola J Topham; Eric W Hewitt
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

Review 6.  The road to lysosome-related organelles: Insights from Hermansky-Pudlak syndrome and other rare diseases.

Authors:  Shanna L Bowman; Jing Bi-Karchin; Linh Le; Michael S Marks
Journal:  Traffic       Date:  2019-06       Impact factor: 6.215

Review 7.  Formation and function of the lytic NK-cell immunological synapse.

Authors:  Jordan S Orange
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

Review 8.  Genetic heterogeneity in severe congenital neutropenia: how many aberrant pathways can kill a neutrophil?

Authors:  Alejandro A Schäffer; Christoph Klein
Journal:  Curr Opin Allergy Clin Immunol       Date:  2007-12

9.  Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems.

Authors:  Thomas R Bauer; Rima L Adler; Dennis D Hickstein
Journal:  ILAR J       Date:  2009

Review 10.  Genetic insights into congenital neutropenia.

Authors:  Christoph Klein; Karl Welte
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.